Edgestream Partners L.P. Takes $1.58 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Edgestream Partners L.P. purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, Holdings Channel.com reports. The fund purchased 4,421 shares of the biotechnology company’s stock, valued at approximately $1,584,000.

Other hedge funds also recently modified their holdings of the company. LSV Asset Management raised its stake in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the period. FMR LLC increased its holdings in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Assetmark Inc. raised its stake in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the period. Pacer Advisors Inc. raised its stake in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in United Therapeutics by 49.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after purchasing an additional 91,597 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,796 shares of United Therapeutics stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84. Following the completion of the transaction, the chief financial officer now owns 4,264 shares in the company, valued at approximately $1,509,626.56. The trade was a 64.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 119,442 shares of company stock worth $44,577,770. 11.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on UTHR shares. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Price Performance

UTHR stock opened at $368.79 on Wednesday. The firm has a 50 day simple moving average of $368.07 and a two-hundred day simple moving average of $336.78. The stock has a market cap of $16.47 billion, a PE ratio of 16.20, a P/E/G ratio of 1.08 and a beta of 0.54. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period in the previous year, the business earned $5.38 earnings per share. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.